News - Appointments

The Swiss pharmaceutical development company MetrioPharm AG, which specialises in drugs for chronic inflammatory diseases, has appointed Thomas Christély as its new chief executive, effective

Tracey Lodie is to join Quell Therapeutics Ltd as chief scientific officer, to be based in Boston, Mass, US.

Lindy Durrant is to become sole chief executive of Scancell Holdings Plc, a company which she founded in 1997 on the basis of research she led at the University of Nottingham, UK.

Compass Pathways Plc has appointed Guy Goodwin as chief medical officer to oversee development of psilocybin, a psychedelic prodrug for treatment-resistant depression.

Julie Krop has been appointed chief medical officer at PureTech Health Plc, a clinical state biotherapeutics company. She joins from the gene therapy company Freeline Therapeutics Holdings Plc where she was also CMO.

Catherine Isted, a chartered accountant and finance professional, has been appointed chief financial officer of ReNeuron Group Plc, the UK-based cell therapy company. Her appointment is effective on 11 October.

Theragnostics Ltd has appointed Dennis Langer and Ken Herrmann as non-executive directors to help  guide development of its radionuclide diagnostics and therapies. Dr Langer formerly held executive positions at Neose Technologies Inc and GlaxoSmithKline Plc.

Mathieu Lane has been appointed chief financial officer of eTheRNA immunotherapies NV as well as president of the Belgian company’s new US subsidiary. Mr Lane has spent more than 15 years in healthcare investment banking in New York, US.

Mikhail Kalinichev has rejoined Addex Therapeutics Ltd as head of translational science as the Switzerland-based company advances its lead product in a registration trial for levodopa induced dyskinesia in Parkinson’s disease.

Ireland-based SynOx Therapeutics Ltd has appointed a new chief executive and non-executive chairman as it prepares to bring the cancer therapy, emactuzumab, into a registrational trial in the US and EU.